Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.
Exploring Alternate Allogeneic Immunotherapy Strategies in Hematologic Oncology
Orca-T was associated with OS, RFS, and NRM improvements in patients with hematologic malignancies who also received myeloablative conditioning.
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5